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Introduction: Epithelial–mesenchymal transition (EMT) contributes to the progression and metastasis of cancer cells
and is associated with a more invasive phenotype of cancer. The Wnt/β-catenin signaling pathway is one of the
major pathways involved in EMT regulation. Many studies provide evidence that β-catenin, the key regulator of the
canonical Wnt signaling pathway, is important in regulating EMT in cancer. However, the roles of Wnt3a, the
representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.
Methods: The expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and β-catenin) were
assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance
of Wnt3a, as well as the correlation between Wnt3a and EMT. We then upregulated Wnt3a expression in HCT116
colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/β-catenin
signaling-associated proteins, and observed invasion and clone-initiating abilities.
Results: In 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer
histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036),
and survival time (P = 0.007) of colon cancer patients. Wnt3a expression was notably concomitant with EMT
immunohistochemical features, such as reduced expression of the epithelial marker E-cadherin (P = 0.012), increased
expression of the mesenchymal marker vimentin (P = 0.002), and cytoplasmic distribution of β-catenin (P = 0.021).
Results of in vitro and in vivo experiments showed that Wnt3a overexpression could alter cell morphology, regulate
EMT-associated protein expression, and enhance clone-initiation and invasion. Dkk1 (antagonist of Wnt/β-catenin
signaling) could also partially reverse the expression of EMT-associated proteins in Wnt3a-overexpressing cells.
Conclusions: Wnt3a expression was associated with EMT and promoted colon cancer progression. The EMT-inducing
effect was partially due to the stimulative effect of Wnt3a on the Wnt/β-catenin pathway.
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Colorectal carcinoma is the third most common cause
of cancer-related deaths worldwide [1]. Although colorec-
tal cancer diagnosis and treatment have significantly ad-
vanced over the past two decades, the five-year survival
rate remains below 50%. More than 50% of colorectal can-
cer cases metastasize to the lymph nodes, liver, and lungs* Correspondence: sunbaocun2014@163.com
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unless otherwise stated.[2]. Thus, knowledge on the treatment of this disease
would advance if its metastasis mechanism is deeply
understood.
Epithelial–mesenchymal transition (EMT) is an early
phase of the malignant transformation of epithelial cells.
In EMT, cells lose their polarities and contacts with neigh-
boring cells and then acquire mesenchymal-like and motile
phenotypes [3]. Tumor-cell EMT is considered a crucial
event in cancer metastasis. Numerous factors can report-
edly induce or mediate EMT, and these factors are com-
monly associated with carcinoma progression.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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esis and development and is also widely implicated in a
number of human diseases [4-6]. Deregulation of the
Wnt signaling pathway has been associated with senes-
cence bypass [7], aberrant cell growth [8], and cancer
[9]. Signaling through the Wnt pathway starts with Wnt
ligands, which consist of more than 19 closely related
but distinct secreted cysteine-rich glycoproteins [10]. By
activating multiple intracellular signaling cascades, Wnts
control various cellular functions, including prolifera-
tion, tissue homeostasis, stem cell maintenance, and cell
fate decisions [11,12]. Several Wnts such as Wnt1,
Wnt3a, and Wnt7a stimulate the β-catenin-dependent
pathway, called canonical Wnt signaling [12]. Other
Wnts such as Wnt4, Wnt5a, and Wnt11 may activate
the protein kinase c, calcium-calmodulin kinase, or Jun
NH (2)-terminal kinase pathway, called non-canonical
Wnt signaling [13].
The canonical Wnt/β-catenin signaling pathway is well
established in colorectal oncogenesis, with >85% of these
malignancies harboring mutations along the pathway
that lead to constitutive activation. Many studies provide
evidence that the Wnt/β-catenin signaling pathway plays
an important role in EMT regulation [14,15]. However,
most investigations on the effects of the canonical Wnt
pathway on EMT have focused on β-catenin rather than
on Wnt ligands despite the role of Wnt proteins as
major initiating factors in the Wnt/β-catenin pathway.
Blavier et al. found that Wnt1 overexpression in murine
mammary epithelial cells in vitro could promote EMT
and cell proliferation [16]. Bo and Kanzawa have shown
that increased Wnt5a provokes EMT of pancreatic can-
cer and gastric cancer cells [17,18]. Wu reported that
Wnt3 activates the Wnt/β-catenin pathway and pro-
motes EMT-like phenotypes in trastuzumab-resistant
HER2-overexpressing breast cancer cells [19]. Bao et al.
found that Wnt3a could promote the EMT, migration,
and proliferation of human lens epithelial cells [20].
Meanwhile, the role of Wnt3a in colorectal cancer EMT
has not been fully explored.
In this study, we evaluated the clinicopathological sig-
nificance of Wnt3a and analyzed the correlation between
Wnt3a expression and EMT immunohistochemical fea-
tures in tissue specimens from 203 colon cancer pa-
tients. The effects of Wnt3a ectopic expression in the
colon cancer cell line HCT116 on the expression of epi-
thelial and mesenchymal markers and EMT transcrip-
tion factors were studied. We also investigated cell
proliferation and invasion in cell cultures with Wnt3a
overexpression, as well as tumor growth and metastasis
in a colon cancer xenograft model. We further treated
Wnt3a-overexpressing cells with a Wnt/β-catenin path-
way antagonist Dkk1-conditioned medium and detected




Tissue samples of colon cancer were harvested from 203
patients who had undergone surgery for colon cancer in
Tianjin Medical University Cancer Institute and Hospital
(Tianjin, China) between January 2002 and December
2004. None of the patients had received any chemother-
apy or radiotherapy before their operation. Data of clini-
copathological parameters were obtained from patients’
clinical records and pathological reports.
Cell culture reagents and animals
The human colon cancer cell line HCT116 was obtained
from the Cell Resource Center at the Institute of Basic
Medical Sciences, Chinese Academy of Medical Sciences/
Peking Union Medical College (Beijing, China). Cells were
cultured in Iscove modified Dulbecco medium with 10%
FBS. Dkk1 recombinant protein was obtained from R&D
Systems. For Dkk1 administration in vitro, recombinant
Dkk1 (1 μg/mL) was added to culture medium. Typically,
50% of the medium was replaced every 24 h with fresh
conditioned medium containing Dkk1 at the original con-
centrations. Cells were harvested 48 h post-treatment, and
total cell lysates were collected for measurement by
Western blot. The micro-Boyden chambers used were
from NeuroProbe (Gaithersburg, MD, USA). Anti-
bodies to β-catenin, goat anti-rabbit, and goat anti-
mouse IgG-FITC were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies to Wnt3a, Snail,
Slug, and Twist were from Abcam (Cambridge, UK).
Antibody to E-cadherin was from BD Biosciences (San
Jose, CA, USA). Antibody to vimentin was from Epitomics
(Burlingame, CA, USA). Phalloidin was from Invitrogen
(Carlsbad, CA, USA). Alexa Fluor 488 and 546 were from
Molecular Probes (Eugene, OR, USA). BALB/C nude mice
(4–5 weeks old) were obtained from Wei Tong Li Hua
Experimental Animal Company (Beijing, China).
Immunohistochemical staining
Streptavidin–biotin–peroxidase staining was performed as
previously described [21]. In a typical procedure, the sec-
tions were pretreated with microwaves, blocked, and incu-
bated with a series of antibodies overnight at 4°C. Then,
they were immunostained with HRP-conjugated antibody
and signals were revealed using 3,3-diaminobenzidine
buffer as substrate. In place of primary antibodies for
the negative control, PBS was used.
The expression of Wnt3a, E-cadherin, vimentin, and
β-catenin was analyzed only histologically in normal
and neoplastic epithelial cells and not in stromal tis-
sues. Wnt3a staining was considered immunoreactive
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The staining intensity of Wnt3a was graded on a scale
from 0 to 2 (0 for no staining, 1 for weak immunoreac-
tivity, 2 for strong immunoreactivity). Percentage im-
munoreactivity was scored on a scale from 0 to 3 (0 for
no positive cells, 1 for <25% of cells being positive, 2 for
25% to 50% of cells being positive, and 3 for >50% of
cells being positive). We multiplied the two scores to
obtain a composite Wnt3a expression score. Wnt3a ex-
pression was classified as negative (score = 0), weakly
positive (score = 1, 2, or 3), or strongly positive (score =
4, 5, or 6). E-cadherin expression was considered to be
positive if >90% of cancer cells exhibited a staining pat-
tern similar to that in normal epithelial cells. Vimentin
expression was classified as positive when >10% cells
were stained. β-Catenin nuclear staining was considered
positive if >10% of cells showed brown granules in
nuclei.
Plasmid transfection
Transfection with plasmid carrying Wnt3a and controlled
scrambled plasmid (Genechem, Shanghai, China) was per-
formed with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
To establish stable HCT116 cells that overexpressed
Wnt3a, G418-resistant cells were screened.
Western blot analysis
Protein (30–50 μg/lane) was separated by 10% SDS-PAGE
and transferred to polyvinylidene difluoride membranes.
Blots were blocked and incubated with primary antibodies
overnight at 4°C, incubated with secondary antibody, and
detected with ECL Western blot substrate (Millipore)
according to the manufacturer’s instructions.
Soft agar colony formation assay
To form bottom agar, 1.5 mL of culture medium con-
taining 0.6% agarose was added to each 35 mm dish.
Then, 1 mL of culture medium containing 0.6% agarose
and 1 × 104 cells were mixed gently at 37°C and plated
onto the bottom agar. Dishes were incubated at 37°C
and 5% CO2. Six days later, colonies (>50 μm) were
counted from 10 random fields per dish.
Matrigel invasion assay
Matrigel (BD Biosciences) with a final concentration of
1.5 mg/mL was added to the upper surface of the cham-
ber filter (8 μm pore). Then, 200 μL of cell suspension
(5 × 105 cells/mL) contained in serum-free medium was
added to the upper chamber, and 300 μL of culture
medium supplemented with 20% FBS was added to the
lower chamber. After incubation for 20 h, the passed
cells were fixed and stained.Immunofluorescence confocal microscopy
Cells were cultured on sterile glass cover slips on the
day before staining. Cells were fixed with 4% paraformal-
dehyde, quenched with 50 mmol/L NH4Cl, permeabilized
in 0.2% Triton X-100, and blocked in 3% BSA. The slips
were incubated with the primary antibodies overnight
at 4°C, labeled with the specific secondary antibodies
for 1 h in the dark, mounted, and visualized with a
confocal laser scanning microscopy (Leica TCS SP5,
Leica Microsystems).
In vivo assay
Twenty mice were randomly and evenly divided into
two groups and given either 3 × 106 control or HCT116
cells overexpressing Wnt3a (clone7) by subcutaneous in-
jection in right groin. Tumor size was measured every
3 days for 21 days. Tumor volumes were calculated
using the following formula: volume = [length(in millime-
ters) × width2[in square millimeters])/2. Tumor samples
were formalin fixed and paraffin embedded.
Statistical analysis
SPSS v.16.0 software (SPSS Inc., Chicago, IL, USA) was
used for data analysis. The associations between Wnt3a
and clinicopathologic parameters and the differential ex-
pression of E-cadherin, vimentin and β-catenin between
different Wnt3a expression level groups were assessed
with Fisher’s exact test and chi-square test. Differences
or correlations between groups were assessed by the
Mann–Whitney U-test, Student’s t-test and Pearson’s
correlation test. Survival analysis was carried out accord-
ing to Kaplan–Meier. Differences in survival curves were
assessed using the log rank test. Significance was set at
P < 0.05.
Results
Wnt3a expression is increased in colon carcinomas and
correlates with the clinical outcome of patients
Among 203 samples, 179 (88.2%) showed positive Wnt3a
expression, whereas the remaining 24 (11.8%) were nega-
tive. Tumors were categorized as strong expression, weak
expression, or negative for Wnt3a (Figure 1A). Relation-
ships between Wnt3a expression levels in colon cancer
and each clinicopathological parameter were analyzed
Table 1). Wnt3a expression level in colon cancer was
found to increase with decreased differentiation grade.
Wnt3a was strongly expressed in samples with higher
clinical stages and metastasis/recurrence. Wnt3a expres-
sion was not significantly correlated with gender, age, and
tumor size. Differences in Wnt3a expression level within
tumors were found, with strong Wnt3a expression ob-
served in tumor cells located close to stroma, implicating
that Wnt3a may be involved in tumor progression in
colon cancer (Figure 1B).
Figure 1 Expression of Wnt3a by immunohistochemical staining in human colon cancer tissue samples. (A) Representative colon cancer
samples with Wnt3a negative (left), weak (middle), and strong (right) expression, 400×. (B) Strong expression of Wnt3a was observed in invasive
front, 200×. (C) Kaplan–Meier survival analysis showing that Wnt3a-negative patients had longer survival time than Wnt3a-weak expression or
Wnt3a-strong expression patients.
Table 1 Correlation between Wnt3a and clinicopathologic characteristics of patients with colon cancer
Viariant Total Wnt3a expression χ2 P Value
Negative (%) Weak expression (%) Strong expression (%)
Age
<45 27 2 (7.4) 17 (63) 8 (29.6) 1.340 0.512
≥45 176 22 (12.5) 117 (66.5) 37 (21.0)
Sex
Male 95 10 (10.5) 68 (71.6) 17 (17.9) 2.563 0.278
Female 108 14 (13) 66 (61.1) 28 (25.9)
Tumor size
≥5 cm 166 6 (9.1) 41 (62.1) 19 (28.8) 2.775 0.250
<5 cm 137 18 (13.1) 93 (67.9) 26 (19.0)
Histological differentiation
Well differentiated 16 5 (31.2) 10 (62.5) 1 (6.2) 15.127 0.004*
Moderately differentiated 101 11 (10.9) 74 (73.3) 16 (15.8)
Poorly differantiated 86 8 (9.3) 50 (58.1) 28 (32.6)
Clinical stage
TNMI 10 5 (50.0) 4 (40.0) 1 (10.0) 17.456 0.008*
TNMII 128 15 (11.7) 86 (67.2) 27 (21.1)
TNMIII 54 4 (7.4) 37 (68.5) 13 (24.1)
TNMIV 11 0 (0.0) 7 (63.6) 4 (36.4)
Metastasis/recurrence
Absent 135 20 (14.8) 91 (67.4) 24 (17.8) 6.674 0.036*
Present 68 4 (5.9) 43 (63.2) 21 (30.9)
*Significantly different.
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that the total survival time for patients in the Wnt3a-
negative group was significantly longer than for those in
the Wnt3a-weak expression or Wnt3a-strong expression
group (P = 0.007). The average survival time for Wnt3a-
negative patients was 76.4 months, whereas the average
survival time for Wnt3a-weak expression and Wnt3a-
strong expression group patients were 57.6 and 41.7 months
respectively (Figure 1C).
Wnt3a expression was concomitant with EMT
immunohistochemical features
To assess the relationship between Wnt3a and EMT in
colon cancer, we investigated the expression of the EMT-
associated markers E-cadherin, vimentin, and β-catenin
(also a marker of Wnt/β-catenin pathway activation). As
shown in Table 2 and Figure 2, the Wnt3a-negative group
showed higher E-cadherin expression and lower vimentin
and nuclear β-catenin expression than the positive group.
β-Catenin was mainly expressed in cytoplasm in the
Wnt3a-negative group and in the nucleus in the positive
group. The expression of Wnt3a correlated with the ex-
pression of E-cadherin (r = −0.208, P < 0.05), vimentin
(r = 0.247, P < 0.001), and β-catenin (nuclear) (r = 0.194,
P < 0.05). These data provided proof about the role of
Wnt3a as a potent activator of Wnt/β-catenin signaling
and as a regulator involved in tumor progression in colon
cancer.
Wnt3a overexpression induced mesenchymal phenotype
and increased expression of Snail in HCT116 cells
We established stable Wnt3a-overexpressed colon can-
cer cells to study the EMT-promoting effect of Wnt3a
on colorectal cancer cells. To rule out clone-to-clone
variations, we selected two clones (clone7 and clone15).
HCT116 cells with Wnt3a overexpression had increased
expression of c-myc and cyclin D1 (Figure 3A), which
are the best-known target proteins of canonical WntTable 2 Correlation between expression of Wnt3a and EMT-a
Variant Total Wnt3a expression
Negative (%) Weak e
E-cadherin expression
Negative 16 0 (0.0) 8 (50.0)
Positive 187 24 (12.8) 126 (67.4
Vimentin expression
Negative 187 24 (12.8) 127 (67.9
Positive 16 0 (0.0) 7 (43.8)
β-catenin nuclear expression
Negative 167 22 (13.2) 114 (68.3
Positive 36 2 (5.6) 20 (55.6)
*Significantly different.signaling [19,20], thereby confirming activation of the
signaling pathway.
EMT is a multistep process in which cells undergo mo-
lecular alterations that facilitate dysfunctional cell–cell ad-
hesive interactions and reorganization of cytoskeleton,
resulting in loss of apical polarity and acquisition of a
more spindle-shaped morphology. Thus, we used phal-
loidin to dye fibrous actin (F-actin), a representative of
cytoskeleton, and observed that Wnt3a overexpression
caused HCT116 cells to form structures with irregular
shape and non-uniform composition or density (Figure 3B).
Western blot and immunofluorescence assays demon-
strated that cells overexpressing Wnt3a had lower expres-
sion of E-cadherin and higher expression of vimentin than
control cells (Figure 3C and 3D). In addition to classical
EMT markers, we examined the expression of the EMT
transcription factors Snail, Slug, and Twist. These markers
could repress E-cadherin expression by direct binding to
the E-boxes of the E-cadherin promoter. Among them,
Snail was upregulated in cells overexpressing Wnt3a com-
pared with control cells, whereas the expression of Slug
and Twist did not significantly change (Figure 3C). More-
over, although total β-catenin expression did not markedly
change in Western blot detection, immunofluorescence
showed that more β-catenin accumulated in the nucleus
of cells overexpressing Wnt3a than in that of control cells
(Figure 3D). All these findings suggested that cells overex-
pressing Wnt3a were more predisposed to mesenchymal
differentiation.
Wnt3a promotes in vitro clone-initiating and invasion abilities,
in vivo tumor growth and metastasis of HCT116 cells
Anchorage-independent growth, one of the most import-
ant malignant features of cancer cell stemness, was found
to be significantly increased in cells overexpressing Wnt3a
(Figure 4A).
Compared with epithelial cells, mesenchymal cells
generally defined cell polarity, cytoskeletal structuresssociated proteins
χ2 P Value
xpression (%) Strong expression (%)
8 (50.0) 8.798 0.012*
) 37 (19.8)
) 36 (19.3) 12.459 0.002*
9 (56.2)
) 31 (18.6) 7.698 0.021*
14 (38.9)
Figure 2 Wnt3a expression was concomitant with EMT immunohistochemical features in human colon cancer tissue samples. E-cadherin
expression was higher in Wnt3a negative (−) or weak expression (+) colon cancer tissue sections than in strong-expression (++) samples. E-cadherin
was mainly localized in membrane of Wnt3a (−)/(+) samples (red arrows) and in cytoplasm of Wnt3a (++) samples (black arrows). Tumor cells in Wnt3a
(−)/(+) section did not express vimentin, whereas several tumor cells in Wnt3a (++) section showed expression of vimentin. In Wnt3a (−)/(+) sections,
tumor cells displayed weak and only membrane-localized β-catenin expression, whereas tumor cells in Wnt3a (++) section showed nuclear β-catenin
accumulation (black arrows), 400×.
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can directly lead to increased invasive potential of
tumor cells. As expected, more cells overexpressing
Wnt3a invaded through the Matrigel than control cells
(Figure 4B).
In agreement with in vitro findings, clone7 cells over-
expressing Wnt3a grew into larger tumor masses than
control cells (Figure 4C). To assess canonical Wnt signal
activity in xenografts, we then performed β-catenin im-
munohistochemical staining on the sections of xenograft
tissues. The nuclear expression of β-catenin significantly
increased in Wnt3a tumors compared with control tu-
mors (Figure 4D). Among the 10 mice injected with
clone7 cells, one showed lung metastasis and one
showed lymph node methastasis (Figure 4E). Meanwhile,
among the 10 mice injected with control cells, no mouse
showed lymph node or lung metastasis and only two
showed tumor invasion into the surrounding fatty tissue.
Dkk1 abolishes the expression of EMT-associated proteins
in Wnt3a-overexpressing HCT116 cells
To verify whether the EMT promotion effect of Wnt3a
was due to Wnt/β-catenin pathway activation, we uti-
lized the Wnt/β-catenin pathway inhibitor Dkk1. Dkk1
functions as an antagonist of the Wnt/β-catenin pathway
by binding to lipoprotein receptor-related protein 5 or 6
(LRP5/6) and preventing the formation of Wnt-Fz-LRP
ternary complexes and the downstream signaling trans-
duction. After Dkk1 treatment, Wnt3a-overexpressing
cells showed decreased β-catenin expression, indicatingthe effectiveness of Dkk1 as an inhibitor of Wnt/β-catenin
pathway. Western blot assays also demonstrated that
Wnt3a-overexpressing cells treated with Dkk1 had
higher expression of E-cadherin and lower expression
of vimentin, Snail, and Twist compared with untreated
cells (Figure 5). This finding indicated that Wnt/β-
catenin pathway activation played an important role in
the EMT-inducing effect of Wnt3a. Meanwhile, Dkk1
did not restore the expression of EMT-associated pro-
teins in Wnt3a-overexpressing cells to the same level
as the control cells, suggesting that Wnt3a may pro-
mote EMT through distinct mechanisms other than
activating the Wnt/β-catenin pathway.
Discussion
Wnt3a is a Wnt protein that activates the canonical
Wnt pathway. Wnt3a stimulates tumor progression in
glioblastoma [22], breast and prostate cancers [23,24],
and malignant mesothelioma [25]. Other studies have
shown that Wnt3a serves as a tumor suppressor based
on two main findings. One is that bones engrafted with
Wnt3a-expressing multiple myeloma H929 cells are pre-
served; the other is that treatment of myelomatous SCID
mice carrying the primary disease with recombinant
Wnt3a stimulates bone formation and attenuates mul-
tiple myeloma growth [26]. Marit et al. reported that
Wnt3a inhibits the proliferation of several B-acute
lymphoblastic leukemia cell lines [27]. In the present
study, we initially analyzed Wnt3a expression in a large
array of colon cancer tissue samples to determine its role
Figure 3 Wnt3a overexpression induced mesenchymal phenotype and increased expression of mesenchymal markers. (A) Wnt3a
protein levels were significantly increased in clone7 and clone15 HCT116 cell pools transfected with Wnt3a plasmid. Then, c-myc and CyclinD1
protein expression increased in clone7 and clone15 HCT116 cell. (B) Immunofluorescent staining of F-actin. Wnt3a-overexpressing cells exhibited
dramatic changes in cell morphology from a tight packed, polarized, and epithelial-like appearance to a scattered, irregular, and fibroblastic-like
shape. (C) Wnt3a-overexpressing cells showed lower E-cadherin expression but higher vimentin expression. β-Catenin expression did not markedly
change in three groups of cells. EMT regulatory proteins including Snail, Slug, and Twist were detected. Snail was upregulated in Wnt3a-overexpressing
cells compared with control cells, whereas Slug and Twist expression did not significantly change. (D) Immunofluorescent staining of E-cadherin, vimentin,
and β-catenin. Wnt3a-overexpressing cells showed lower E-cadherin expression and higher vimentin expression. More β-catenin accumulation in nucleus
was observed in Wnt3a-overexpressing cells than in control cells. A green or red signal represents staining for corresponding protein, whereas a blue
signal represents nuclear DNA staining by 4′,6-diamidino-2-phenylindole.
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correlation between Wnt3a expression and histological
differentiation, clinical stages, metastasis, and recur-
rence, indicating that the upper stream factor of the
Wnt signaling pathway may play an important role in
colon-cancer progression. This result was consistent
with a recent study on colorectal cancer, in which re-
sults reveal that Wnt3a is highly expressed in the pri-
mary and metastatic sites and is significantly associated
with expression of the metastasis-related protein matrix
metalloproteinase (MMP)-9 [28].
EMT is involved in numerous normal developmental
processes and in cancer progression. EMT involves bio-
chemical changes that result in decreased expression of
the epithelial marker E-cadherin but increased expressionof mesenchymal markers, such as vimentin. Cancer cells
undergoing EMT are suitable for migration, invasion, and
proliferation, thereby facilitating tumor progression. EMT
involves different regulatory signaling pathways. Although
the effects of Wnt/β-catenin signaling in promoting EMT
during physiological or pathological processes have been
extensively studied, the present study was the first to dem-
onstrate the EMT-inducing ability of Wnt3a in colon can-
cer. In human colon cancer tissue samples, lower levels of
E-cadherin expression, as well as higher levels of vimentin
expression and β-catenin nuclear distribution, were ob-
served in the Wnt3a strong group than in the weak and
negative expression groups. This finding suggested that
Wnt3a may contribute to EMT in colon cancer. EMT in-
duction in colon cancer cells by Wnt3a was confirmed
Figure 4 Effect of Wnt3a overexpression on in vitro clone-initiation and invasion abilities and in vivo tumor growth and metastasis.
(A) Wnt3a overexpression promoted HCT116 anchorage-independent growth in soft agar. Colonies in soft agar culture were stained (left), 200×.
Histogram showing colony formation efficiency (right). (B) Cells invading through matrigel-coated transwell inserts were stained (left), 200×.
Invading cells were counted in five pre-determined fields (right), 400×. (C) Photograph of representative tumors from mice injected with
control or Wnt3a transfected HCT116 cells (clone7) (left). Wnt3a-overexpressing cells produced larger tumor masses than control cells (right).
(D) Immunohistochemical staining of β-catenin expression in harvested mouse tumor samples. Tumors overexpressing Wnt3a (clone7) exhibited
increased nuclear β-catenin expression compared with control tumors, 400×. (E) Mice injected with Wnt3a-overexpressing cells (clone7) showed lymph
node metastasis and lung metastasis (red arrows); hematoxylin and eosin staining, 200 × .
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Figure 5 Dkk1 disrupted the expression of EMT-associated
proteins in Wnt3a overexpressing HCT116 cells. After Dkk1
treatment, Wnt3a-overexpressing cells showed decreased
β-catenin, vimentin, Snail, and Twist, expression but increased
E-cadherin expression.
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EMT-associated markers, as well as enhanced invasion
capacities. Moreover, previous reports have indicated that
cancer cells undergoing EMT share the properties of stem
cell-like cells [29-31].
In the present study, we found that Wnt3a overex-
pression could promote colon-cancer cell growth in
anchorage-independent growth in soft agar and in-
creased the expression of c-myc, which is a major tar-
get molecule of transcription T-cell factor/lymphoid
enhancer factor (TCF/LEF) promoter and also a cancer
stem cell marker. We further demonstrated that Wnt3a
could promote the expression of Snail, which is a key tran-
scription EMT regulator. We also found that Wnt3a has
significant stimulative effects on tumor growth and metas-
tasis in nude mice. These findings demonstrated that ec-
topic Wnt3a expression exerted EMT-inducing effects
that promote the progression of colon cancer. Meanwhile,
another study on hepatocellular carcinoma showed that
recombinant Wnt3a could not induce Huh-7 or HepG2
cells to undergo EMT in normoxia. Yoshida also indicated
that oxidative stress could induce canonical Wnt activation.All these observations emphasize the importance of the
microenvironment for Wnt signaling and EMT [32,33].
We suggested that the inconsistencies may be attrib-
uted to the different cell types and tissues.
β-Catenin has a dual cellular function and is involved
in both transcription regulation and cell adhesion. When
Wnt ligands such as Wnt1, Wnt3a, and Wnt7a act on
their cell-surface receptors, cytoplasmic β-catenin is sta-
bilized by its release from the axin complex and accu-
mulation in the nucleus, where it binds to TCF/LEF and
stimulates the expression of various genes involved in
EMT [34]. β-Catenin has also been identified as a
cadherin-binding protein. The nuclear translocation of
β-catenin leads to the breakdown of cell-to-cell adhesion
formed by β-catenin and E-cadherin. This phenomenon
has been extensively studied in both morphological and
biochemical EMT processes regardless of inducers and
origins [35]. Our results showed that ectopic Wnt3a
expression in HCT116 increased the expression and
intracellular distribution of β-catenin and of the well-
established target proteins of Wnt/β-catenin signaling,
namely, c-myc, and cyclin D1. However, the inhibition
of Wnt/β-catenin signaling by Dkk1 disrupted Wnt3a-
induced EMT. All results indicated that the EMT-
inducing effect of Wnt3a in colon cancer may be at
least partially due to the stimulative effect of Wnt3a on
the Wnt/β-catenin pathway.
After treating with Dkk1, the expression of EMT-
associated proteins in Wnt3a-overexpressing cells did
not recover to the same level as that of control cells.
Thus, a Wnt3a-induced EMT mechanism that is inde-
pendent of the Wnt/β-catenin pathway may exist. Another
possibility was that the cancer cells may be responsive to
Dkk1 differently in 2-D versus 3-D cultures, which more
closely mimic the in vivo environment [36,37].
Multiple interactions were observed between Wnt3a
and other families of signaling molecules, such as FAK,
TGF-β, and EGF [38-41]. Nalesso reported that Wnt3a
could activate both canonical and non-canonical Wnt
pathways in the articular chondrocyte [42]. Sonderegger
reported that Wnt3a could activate phosphatidylinositide3-
kinase (PI3K)/AKT signaling, which could potentially
cross-talk to canonical Wnt signaling and affect MMP-2
secretions to promote the invasion of human trophoblasts
[43]. Studies designed to elucidate the interactions of
Wnt3a with other EMT-associated signaling pathways
in colon cancer are currently under way.
In conclusion, we showed that Wnt3a expression ac-
tivated the Wnt/β-catenin signaling pathway, and this
activation was a mechanism underlying EMT in colon
cancer. The results provide better understanding of the
importance of EMT in tumor development and may
enable the establishment of clinically useful therapy
targets.
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